These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
130 related items for PubMed ID: 16203141
21. Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships. Sham HL, Betebenner DA, Rosenbrook W, Herrin T, Saldivar A, Vasavanonda S, Plattner JJ, Norbeck DW. Bioorg Med Chem Lett; 2004 May 17; 14(10):2643-5. PubMed ID: 15109669 [Abstract] [Full Text] [Related]
22. Predictors of virologic response to ritonavir-boosted protease inhibitors. Marcelin AG, Flandre P, Peytavin G, Calvez V. AIDS Rev; 2005 May 17; 7(4):225-32. PubMed ID: 16425962 [Abstract] [Full Text] [Related]
23. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure. Mimoto T, Nojima S, Terashima K, Takaku H, Shintani M, Hayashi H. Bioorg Med Chem; 2008 Feb 01; 16(3):1299-308. PubMed ID: 17981045 [Abstract] [Full Text] [Related]
24. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties. Ami E, Nakahara K, Sato A, Nguyen JT, Hidaka K, Hamada Y, Nakatani S, Kimura T, Hayashi Y, Kiso Y. Bioorg Med Chem Lett; 2007 Aug 01; 17(15):4213-7. PubMed ID: 17537628 [Abstract] [Full Text] [Related]
26. Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors. Yanada R, Koh Y, Nishimori N, Matsumura A, Obika S, Mitsuya H, Fujii N, Takemoto Y. J Org Chem; 2004 Apr 02; 69(7):2417-22. PubMed ID: 15049639 [Abstract] [Full Text] [Related]
32. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design. Perryman AL, Lin JH, Andrew McCammon J. Chem Biol Drug Des; 2006 May 05; 67(5):336-45. PubMed ID: 16784458 [Abstract] [Full Text] [Related]
34. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency. Han Q, Chang CH, Li R, Ru Y, Jadhav PK, Lam PY. J Med Chem; 1998 Jun 04; 41(12):2019-28. PubMed ID: 9622543 [Abstract] [Full Text] [Related]